CDCP1 AND BREAST CANCER

摘要

The present invention relates to a method for treating breast cancer in a subject having a hyperactivation of the Epidermal Growth Factor Receptor 1 and/or 2 (EGFR and/or ErbB2 HER2), as compared to the normal subject population, or expressing deltaHER2, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the CUB domain-containing protein 1 (CDCP1).